NCT00000511 arm group 2b02a531e3e55d5b989b0db65b5c7e92 [clinicaltrials_resource:NCT00000511/arm-group/2b02a531e3e55d5b989b0db65b5c7e92]
mineral supplements [clinicaltrials_resource:092034a4e0b3564e3613e1fb72c62722]dietary supplements [clinicaltrials_resource:ab9b2626ba276a80435d28c19f727c34]Trial 1: fatty acids, omega-3; Trial 2: Mineral supplements [clinicaltrials_resource:dc99cbfb94bc7447d2b747a0dccea6ff]Polyunsaturates and KCL to Control Mild Hypertension [clinicaltrials:NCT00000511]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00000511 arm group 2b02a531e3e55d5b989b0db65b5c7e92 [clinicaltrials_resource:NCT00000511/arm-group/2b02a531e3e55d5b989b0db65b5c7e92]
Bio2RDF identifier
NCT00000511/arm-group/2b02a531e3e55d5b989b0db65b5c7e92
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 02a531e3e55d5b989b0db65b5c7e92
description [clinicaltrials_vocabulary:description]
Parallel study design, 4 treatment groups
identifier
clinicaltrials_resource:NCT00000511/arm-group/2b02a531e3e55d5b989b0db65b5c7e92
title
NCT00000511 arm group 2b02a531e3e55d5b989b0db65b5c7e92
@en
type
label
NCT00000511 arm group 2b02a531 ...... 2a531e3e55d5b989b0db65b5c7e92]
@en